Monoclonal antibodies

#Autoimmune disease #Cell therapy #Immuno-oncology #Kiji Therapeutics #Mergers and acquisitions #Monoclonal antibodies #REGiMMUNE #Stem cells

REGiMMUNE and Kiji Therapeutics announce intention to merge

Biopharmaceutical company REGiMMUNE and biotech Kiji Therapeutics have announced an intention to merge, creating a global Treg specialist that will target multiple indications. The new company, called REGiMMUNE/Kiji TX will combine the complimentary portfolio of platforms and therapies to create an international Treg biotech. Both companies have been focused on… Read More

#Business & Investment #News

Vaccine research
#Biologics #Chiesi #Manufacturing #Monoclonal antibodies

Chiesi opens €400m Biotech Center of Excellence in Italy

Chiesi Group has launched its Biotech Center of Excellence, dedicated to developing and producing monoclonal antibodies, enzymes, and other proteins, in Parma, Italy. From the production of drug substances from mammalian cells to their transformation into drug products and final packaging, the company says that everything will be done in… Read More

#Business & Investment #News

Antibodies
#Antibody discovery workflow #Biosafety testing #Infographic #Manufacturing #Monoclonal antibodies

Infographic: Discover how to optimise mAb manufacturing

A new Infographic is now available to download from Thermo Fisher Scientific, entitled ‘Optimize Your mAb Manufacturing with Proven Analytical Strategies‘. Key takeaways: Boost Workflow Efficiency: Discover how end-to-end testing can enhance the efficiency of your monoclonal antibody production process. Ensure Compliance: Learn about the importance of accurate and… Read More

#News

#Antibody discovery workflow #Biosafety testing #Manufacturing #Monoclonal antibodies

Optimize Your mAb Manufacturing with Proven Analytical Strategies

Key takeaways: Boost Workflow Efficiency: Discover how end-to-end testing can enhance the efficiency of your monoclonal antibody production process. Ensure Compliance: Learn about the importance of accurate and precise testing at various production stages to meet or exceed regulatory guidelines. Guarantee Quality: Understand how proper testing ensures product safety, quality, and potency throughout… Read More

#Intelligence #Resources

Monoclonal antibody
#Antibody discovery workflow #Case study #Monoclonal antibodies #Stability characterisation

Pierre Fabre enhances its antibody developability platform

A new case study is now free to download entitled ‘How Pierre Fabre Laboratories enhances their antibody developability platform with NanoTemper’s Prometheus Panta.’ In this case study, learn how Dr Elsa Wagner from Pierre Fabre Laboratories put together a comprehensive developability platform for monoclonal… Read More

#News

#Antibody discovery workflow #Monoclonal antibodies #Stability characterisation

How Pierre Fabre Laboratories enhances their antibody developability platform with NanoTemper’s Prometheus Panta

In this case study, learn how Dr Elsa Wagner from Pierre Fabre Laboratories put together a comprehensive developability platform for monoclonal antibodies (mAbs), using combined thermal and colloidal stability parameters from the Prometheus Panta instrument. You’ll learn about: How Pierre Fabre Laboratories approaches developability assessment… Read More

#Resources

#Antibody-based therapeutics #Immunotherapy #Monoclonal antibodies #Oncology

New DDW Highlights episode: 30 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The publication of DDW’s latest eBook on immunotherapy has coincided… Read More

#News

#Chronic obstructive pulmonary disease (COPD) #Monoclonal antibodies #Regeneron Pharmaceuticals #Sanofi

First biologic drug for COPD gets green light in US and China

Dupixent (dupilumab) has become the first biologic medicine for chronic obstructive pulmonary disease (COPD) in the US and China. Sanofi and Regeneron secured approvals from both the US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) in the same week. It is approved for adults with… Read More

#News #Regulatory

#Antibody-based therapeutics #Immunotherapy #Monoclonal antibodies #Oncology

This week in drug discovery (23-27 September) 

News round-up for 23-27 September by DDW Senior Digital Content Editor Diana Spencer. The publication of DDW’s latest eBook on immunotherapy has coincided with some interesting developments in this therapy area, particularly monoclonal antibodies, including two new regulatory approvals. The top stories: Innovent… Read More

#News

FDA headquarters
#FDA #Monoclonal antibodies #Myeloma #Oncology #Sanofi

FDA approves Sarclisa combination for multiple myeloma

The US Food and Drug Administration (FDA) has approved Sanofi’s anti-CD38 monoclonal antibody isatuximab-irfc (Sarclisa) for newly diagnosed multiple myeloma. It is approved in combination with bortezomib, lenalidomide, and dexamethasone for adults with who are not eligible for autologous stem cell transplant (ASCT). The efficacy of the treatment was evaluated… Read More

#News #Regulatory

Monoclonal antibody
#ESMO #Innovent #Monoclonal antibodies #Oncology #Solid tumours

Innovent updates ESMO 2024 on mAbs in solid tumours

Innovent Biologics revealed clinical data on two of its mAb (monoclonal antibody) programmes at the 2024 ESMO Congress. In a Phase I/II study in advanced solid tumours, IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) has demonstrated an excellent safety profile. A total of 368 participants… Read More

#News #Trending News

X-ray showing colon cancer
#Colorectal cancer #Janssen #Monoclonal antibodies #Oncology #Phase II trial

Metastatic colon cancer: 49% response for combination therapy

Janssen-Cilag has shared new data from the Phase Ib/II OrigAMI-1 study at the European Society of Medical Oncology (ESMO) 2024 Congress. The results show that amivantamab combined with chemotherapy demonstrated promising antitumour activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not… Read More

#Cancer Research #News #Trending News

Monoclonal antibody
#Dermatology #Monoclonal antibodies #Orphan drugs #Sanofi

Biologic achieves improvements in bullous pemphigoid

A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) has met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. In the study, five times more Dupixent patients achieved sustained disease remission compared to those on placebo. Read More

#News

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

New DDW Highlights podcast: 2 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the launch of an international clinical trial investigating BioNTech’s mRNA lung cancer vaccine… Read More

#News

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

New DDW Highlights vodcast: 2 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   With the launch of an… Read More

#News

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

This week in drug discovery (26-30 August) 

News round-up for 26-30 August by DDW Senior Digital Content Editor Diana Spencer. With the launch of an international clinical trial investigating BioNTech’s mRNA lung cancer vaccine announced this week, our news highlights focus on clinical trials, including studies of a monoclonal antibody and small molecule GLP-1 agonist for… Read More

#News